Page last updated: 2024-10-15

olanzapine-fluoxetine combination

Description

olanzapine-fluoxetine combination: used to treat bipolar depression [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135659058
MeSH IDM0474509

Synonyms (7)

Synonym
olanzapine-fluoxetine combination
benzenepropanamine, n-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, hydrochloride, mixt. with 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno(2,3-b)(1,5)benzodiazepine
olanzapine and fluoxetine hydrochloride
250603-12-4
DTXSID30947919
n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine--2-methyl-4-(4-methylpiperazin-1-yl)-5h-thieno[2,3-b][1,5]benzodiazepine--hydrogen chloride (1/1/1)
hbixlcdcnxkwjo-uhfffaoysa-n

Toxicity

ExcerptReference
" Treatment-emergent adverse events with OFC (SP1 and SP2) included increased appetite, increased weight, somnolence, anxiety, insomnia, and depressed mood."( Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
Diaz, B; Fumero, I; Jamal, HH; Mattei, MA; Sutton, VK; Tamayo, JM; Tohen, M; Vieta, E; Zarate, CA, 2009
)
" There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events."( Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014
)
" We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
" Adverse effects and all-cause/specific-cause discontinuation were similar across all comparisons."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
"Lamotrigine was superior to placebo in improving unipolar and bipolar depressive symptoms, without causing more frequent adverse effects/discontinuations."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)

Pharmacokinetics

ExcerptReference
" The method was successfully applied to a pharmacokinetic study of fixed dose combination of Olanzapine/Fluoxetine in healthy male volunteers."( Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application.
Bhadane, RP; Bonde, SL; Gaikwad, A; Gavali, SR; Katale, DU; Narendiran, AS, 2014
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (23.53)29.6817
2010's24 (70.59)24.3611
2020's2 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (25.00%)5.53%
Reviews15 (41.67%)6.00%
Case Studies2 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other10 (27.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]